Clinical Trials
Dive into the world of clinical trials, where medical innovations are put to the test. Discover ongoing trials, their methodologies, and results. Stay informed about the latest breakthroughs and promising treatments in development. Understand the rigorous process of bringing new therapies to market.
Akero fails to meet NASH trial endpoint, hurting other players in the field
The landscape of Nonalcoholic Steatohepatitis (NASH) appeared promising with Madrigal Therapeutics taking steps toward treatment approval. However, this optimism was ...
Semaglutide’s Remarkable Success in Kidney Disease Trial Prompts Early Completion
In a recent development surrounding the study of injectable semaglutide’s efficacy in chronic kidney disease, Novo Nordisk has found reason ...
Rocheās Ocrevus shows similar efficacy and safety in subcutaneous and intravenous forms
Roche’s innovative subcutaneous adaptation of its highly-regarded multiple sclerosis (MS) medication, Ocrevus, has achieved a significant breakthrough in a pivotal ...
Roche’s Vabysmo Preserves RVO Patients’ Vision with 4-Month Treatment Intervals in Phase III Trials
Roche has unveiled promising long-term findings from the global phase III BALATON and COMINO trials, which investigated the extended treatment ...
Novartis halts depression drug trial, putting $210M Cadent buyout at risk
Novartis has made the decision to discontinue a mid-phase program aimed at treating major depressive disorder (MDD) with the investigational ...
Ventyx reports positive phase 2 data for bowel disease drug, but fails to impress investors amid competition
Investors have shown skepticism toward Ventyx Biosciences’ attempt to challenge Bristol Myers Squibb and Pfizer in the ulcerative colitis market. ...
Immunicās MS drug shows positive biomarker results in phase 2 trial, boosting investor confidence
Immunic Therapeutics’ strategic decision to refocus its efforts earlier this year appears to be yielding positive results, drawing favorable reactions ...
Merckās Keytruda extends survival of early lung cancer patients in trial, awaits FDA approval
Merck & Co.’s Keytruda has achieved a groundbreaking milestone in the treatment landscape for early-stage non-small cell lung cancer (NSCLC), ...
Anaptys reports positive results for its rare skin disease drug and seeks a partner for commercialization
AnaptysBio has unveiled promising phase 3 data for its rare skin disease drug candidate, indicating a potential challenge to Boehringer ...
Innate Pharma halts lymphomas trials after patient death, but key study continues
Innate Pharma has encountered a safety issue in its lymphoma program, resulting in the FDA imposing a partial clinical hold ...
Neurocrine reports positive phase 3 data for hyperplasia drug in children
Just a month after the successful outcome of Neurocrine Biosciences’ phase 3 study for crinecerfont in adults with hyperplasia, the ...
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
FDA Flags Issues in Galderma’s Botulinum Toxin Filing
While Galderma seeks to expand its range of injectable aesthetic treatments by gaining FDA approval for addressing crow’s feet and ...
ALX Oncology’s CD47 Drug Shows Enhanced Response in Solid Tumors, Aiming for Phase 3 Trials
ALX Oncology is reevaluating the potential of its anti-CD47 drug in the context of solid tumors, buoyed by promising data. ...
Novartisā iptacopan impresses in phase 3 trial for rare kidney disease
Novartis is celebrating a significant achievement as its investigational oral factor B inhibitor reaches a crucial milestone in a phase ...
Syndax Halts Pivotal Cancer Trial Prematurely Due to Efficacy, Stock Dips Amid Disappointing Details
Syndax Pharmaceuticals, based in Massachusetts, has made a significant decision to prematurely conclude a pivotal cancer clinical trial, leading to ...
Pneumagenās nasal spray shows promise in preventing and treating flu infections, phase 2 trial reveals
Pneumagen, the Scottish pharmaceutical company, has achieved a significant breakthrough in the fight against influenza through an unconventional approach to ...
Venclexta fails to meet primary endpoint in multiple myeloma trial
AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...
Structure posts promising results for oral obesity drug, but delays further data due to error
Structure Therapeutics has offered an initial glimpse into the effectiveness of its oral GLP-1 receptor agonist, reporting a notable 5% ...
J&Jās Rybrevant combination therapy beats AZās Tagrisso in lung cancer trial
In a highly anticipated head-to-head battle between Johnson & Johnson’s combination therapy and AstraZeneca’s Tagrisso as a first-line treatment for ...
Bionomicsā PTSD drug shows positive results in phase 2 trial, boosting its share price
Bionomics is making a remarkable resurgence following a significant setback caused by the failure of an anxiety trial, with investors ...
Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis
Evommune, a California-based biotech company, has made the strategic decision to discontinue its sole clinical-stage asset, EVO101, following a thorough ...
Magrolimab fails to improve survival in leukemia, Gilead halts trial
Another failure has occurred in Gilead Sciences’ $4.9 billion immuno-oncology wager. Following an ad hoc analysis of a phase 3 ...
Galecto slashes workforce, explores options after failed fibrosis trial
Boston-based biotech firm Galecto is facing a significant workforce reduction of 70%, affecting 29 employees, following the discontinuation of its ...
Roivantās IMVT-1402 lowers IgG without cholesterol or albumin issues, boosting CEO Glineās debut
Roivant CEO Matt Gline faced an immediate challenge in 2021 when he took the helm, discovering that Immunovant’s lead asset ...
AM-Pharma lays off staff and changes CEO after failed phase 3 trial of ilofotase alfa
After experiencing a setback in its phase 3 study for sepsis-associated acute kidney injury (SA-AKI), Dutch biotech company AM-Pharma is ...
Influential Pliant Persuades Investors, Propelling Stock Skyward with Promising Liver Disease Efficacy Data
Pliant Therapeutics has captured the attention of investors with compelling early clinical findings regarding its lead drug candidate’s potential to ...
Ionisā olezarsen slashes triglycerides and pancreatitis in rare disease patients
Ionis Pharmaceuticals has achieved a significant milestone in its phase 3 clinical trial for lipid-lowering therapy, bringing the company closer ...
Novartis Eyes on First-Line Radiotherapy Role for Lutathera Following Triumph in Neuroendocrine Tumors Trial
Over half a decade since its inaugural FDA approval, Novartis is championing promising trial outcomes for Lutathera, positioning it as ...
Contamination Worries Prompt Scynexis to Recall Brexafemme, Putting Trials on Hold Following GSKās Manufacturing Review
In a surprising development, Scynexis is taking a precautionary step to withdraw its antifungal medication, ibrexafungerp, marketed as Brexafemme, from ...
